TK2d

News

People living with thymidine kinase 2 deficiency (TK2d), a vanishingly rare and often fatal genetic disorder, finally have an approved therapy.

News

UCB's experimental medicine for TK2d, currently under regulatory review, offers hope to patients with the devastating rare disease.

Oncology

As the ESMO26 Congress commences in Madrid, pharmaphorum invited Syncromune Executive Chairman Dr Chuck Link onto the podcast.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.